ArticleMethods in molecular biology (Clifton, N.J.)2019
Leveraging Big Data to Transform Drug Discovery.
Article in Methods in molecular biology (Clifton, N.J.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- The Computational Revolution in Natural Product Research: A Data-Driven Roadmap for Next-Generation Drug Development.Biology · 2026Review
- Foundational model aided automatic high-throughput drug screening using self-controlled cohort study.medRxiv : the preprint server for health sciences · 2024Article
- Computational drug discovery pipelines identify NAMPT as a therapeutic target in neuroendocrine prostate cancer.Clinical and translational science · 2024Article
- Accelerating drug discovery and repurposing by combining transcriptional signature connectivity with docking.Science advances · 2024Article
- Article
- Drug repositioning targeting glutaminase reveals drug candidates for the treatment of Alzheimer's disease patients.Journal of translational medicine · 2023Article
- Artificial intelligence and machine-learning approaches in structure and ligand-based discovery of drugs affecting central nervous system.Molecular diversity · 2023Review
- Artificial Intelligence, Machine Learning, and Big Data for Ebola Virus Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Genome-wide Signatures of Early-Life Stress: Influence of Sex.Biological psychiatry · 2022Review
- Review
- OCTAD: an open workspace for virtually screening therapeutics targeting precise cancer patient groups using gene expression features.Nature protocols · 2021Article
- Big data and artificial intelligence in future patient management. How is it all started? Where are we at now? Quo tendimus?Advances in laboratory medicine · 2020Review
- Development of digital health management systems in longitudinal study: The Malaysian cohort experience.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The surge of public disease and drug-related data availability has facilitated the application of computational methodologies to transform drug discovery. In the current chapter, we outline and detail the various resources and tools one can leverage in order to perform such analyses. We further describe in depth the in silico workflows of two recent studies that have identified possible novel indications of existing drugs. Lastly, we delve into the caveats and considerations of this process to enable other researchers to perform rigorous computational drug discovery experiments of their own.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.